Further, the highest rate of amplification was in TNBC (3.2-6.7%), ER− (2.8-5.4%) and ER−/HER2+ tumors (1.3-6.5%), whereas EGFR amplification was relatively less common in ER+ breast cancers (0.8-1.4%). Here, EGFR is linked to breast cancer.